Log in
(Ad)
If you're looking to potentially make 1,000% in gains, then you NEED this biotech stock. This company discovered a medical breakthrough that may end heart attacks FOREVER! Estimated annual sales are $60 billion. The FDA has all but said it's going to approve the drug. Once that happens, the stock price could double overnight. But you must be onboard BEFORE FDA approval.

NASDAQ:PSNL - Personalis Stock Price, Forecast & News

$12.05
+0.66 (+5.79 %)
(As of 01/23/2020 06:55 AM ET)
Today's Range
$11.37
Now: $12.05
$12.27
50-Day Range
$8.85
MA: $10.34
$12.40
52-Week Range
$8.48
Now: $12.05
$31.88
Volume540,000 shs
Average Volume550,317 shs
Market Capitalization$376.32 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves approximately 45 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSNL
CUSIPN/A
CIKN/A
Phone650-752-1300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees147
Market Cap$376.32 million
Next Earnings Date2/12/2020 (Estimated)
OptionableNot Optionable

Receive PSNL News and Ratings via Email

Sign-up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Join a small community of investors looking for the next big winner. Every Sunday reveals 3 compelling stocks that should be on your radar for the week ahead. Sign up here to see what stocks have made it to our watchlist this week.

Personalis (NASDAQ:PSNL) Frequently Asked Questions

What is Personalis' stock symbol?

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

How were Personalis' earnings last quarter?

Personalis (NASDAQ:PSNL) posted its earnings results on Wednesday, November, 13th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.03. The business had revenue of $17.20 million for the quarter, compared to analysts' expectations of $15.77 million. Personalis's revenue for the quarter was up 47.0% on a year-over-year basis. View Personalis' Earnings History.

When is Personalis' next earnings date?

Personalis is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Personalis.

What guidance has Personalis issued on next quarter's earnings?

Personalis updated its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$64.5-65 million, compared to the consensus revenue estimate of $$61.68 million.

What price target have analysts set for PSNL?

5 brokers have issued 1-year price targets for Personalis' shares. Their forecasts range from $22.00 to $29.00. On average, they expect Personalis' stock price to reach $26.25 in the next twelve months. This suggests a possible upside of 117.8% from the stock's current price. View Analyst Price Targets for Personalis.

What is the consensus analysts' recommendation for Personalis?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Personalis.

Has Personalis been receiving favorable news coverage?

Press coverage about PSNL stock has trended somewhat negative on Thursday, according to InfoTrie. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Personalis earned a coverage optimism score of -1.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Personalis.

Are investors shorting Personalis?

Personalis saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,270,000 shares, an increase of 23.3% from the December 15th total of 1,030,000 shares. Based on an average daily trading volume, of 403,200 shares, the short-interest ratio is presently 3.1 days. Approximately 7.8% of the company's stock are short sold. View Personalis' Current Options Chain.

Who are some of Personalis' key competitors?

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Alibaba Group (BABA), Verizon Communications (VZ), Cisco Systems (CSCO), Editas Medicine (EDIT), CVS Health (CVS), Home Depot (HD), Honeywell International (HON), Pfizer (PFE), Raytheon (RTN) and Thermo Fisher Scientific (TMO).

Who are Personalis' key executives?

Personalis' management team includes the folowing people:
  • Mr. John West, Co-Founder, CEO, Pres & Director (Age 62)
  • Prof. Russ B. Altman M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
  • Mr. Euan A. Ashley, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Atul Butte, Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Michael Snyder Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board

When did Personalis IPO?

(PSNL) raised $100 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Oppenheimer was co-manager.

When did Personalis' lock-up period expire?

Personalis' lock-up period expired on Tuesday, December 17th. Personalis had issued 7,921,500 shares in its IPO on June 20th. The total size of the offering was $134,665,500 based on an initial share price of $17.00. Since the end of Personalis' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are Personalis' major shareholders?

Personalis' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FNY Investment Advisers LLC (0.17%). View Institutional Ownership Trends for Personalis.

Which institutional investors are buying Personalis stock?

PSNL stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. View Insider Buying and Selling for Personalis.

How do I buy shares of Personalis?

Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Personalis' stock price today?

One share of PSNL stock can currently be purchased for approximately $12.05.

How big of a company is Personalis?

Personalis has a market capitalization of $376.32 million. Personalis employs 147 workers across the globe.View Additional Information About Personalis.

What is Personalis' official website?

The official website for Personalis is http://www.personalis.com/.

How can I contact Personalis?

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]


MarketBeat Community Rating for Personalis (NASDAQ PSNL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  91
MarketBeat's community ratings are surveys of what our community members think about Personalis and other stocks. Vote "Outperform" if you believe PSNL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSNL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel